NCT03529942View on ClinicalTrials.gov

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

PHASE3CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

April 24, 2018

Primary Completion Date

November 8, 2019

Study Completion Date

March 9, 2020

Conditions
Osteoarthritis, Knee
Interventions
DRUG

FX006 32 mg

Extended-release 32 mg FX006 IA injection

Trial Locations (10)

16635

Altoona Center for Clinical Research, Duncansville

27710

Duke University Medical Center, Durham

33761

Tampa Bay Medical Research, Inc., Clearwater

37938

PMG Research, Inc. d/b/a PMG Research of Knoxville, Knoxville

60612

Rush University Medical Center, Chicago

91767

Dream Team Clinical Research (formerly located in Anaheim), Pomona

Dream Team Clinical Research, Pomona

91942

Biosolutions Research, La Mesa

92020

TriWest Research Associates, LLC, El Cajon

LS7 4SA

University of Leeds, Leeds

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY